<span item_type="fundamental" item_id="78f0e70eeff528c22f355a5de8c02baa" counter_id="ST/US/BFRIW" env="prod"></span><span item_type="announcement" item_id="549082420940248961" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 9.03 M.</p><p>EPS: As of FY2025 Q2, the actual value is USD -0.57.</p><p>EBIT: As of FY2025 Q2, the actual value is USD -5.166 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Product Revenues, Net</strong>: $9,030 thousand for the three months ended June 30, 2025, compared to $7,831 thousand for the same period in 2024, representing a 15.3% increase. For the six months ended June 30, 2025, product revenues were $17,617 thousand, compared to $15,732 thousand in 2024, a 12.0% increase.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000164117225023486/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: - $5,324 thousand for the three months ended June 30, 2025, compared to - $257 thousand for the same period in 2024. For the six months ended June 30, 2025, net loss was - $9,527 thousand, compared to - $10,694 thousand in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000164117225023486/form10-q.htm"></span></li><li><strong>Loss from Operations</strong>: - $5,079 thousand for the three months ended June 30, 2025, compared to - $5,071 thousand for the same period in 2024. For the six months ended June 30, 2025, loss from operations was - $9,629 thousand, compared to - $10,538 thousand in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000164117225023486/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $7,162 thousand for the six months ended June 30, 2025, compared to - $8,045 thousand for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000164117225023486/form10-q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $8,500 thousand for the six months ended June 30, 2025, compared to $11,083 thousand in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000164117225023486/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Change in Fair Value of Warrant Liabilities</strong>: $153 thousand for the three months ended June 30, 2025, compared to $5,438 thousand for the same period in 2024. For the six months ended June 30, 2025, the change was $702 thousand, compared to $2,009 thousand in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000164117225023486/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to expand sales of Ameluz® in the United States and position it as the standard of care for actinic keratoses. The strategic transaction with Biofrontera AG will allow the company to acquire all U.S. rights to Ameluz® and RhodoLED®, with a royalty structure replacing the previous transfer pricing model.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000164117225023486/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is working on divesting its Xepi product line, with the sale expected to be completed within the next three months.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000164117225023486/form10-q.htm"></span></li></ul>

BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 9.03 M